February 29, 2016

Nick Manetto Discusses Incentives for Rare-Disease Drug Development in Medical Marketing & Media

The orphan drug market has grown at a “feverish pace” since 2013, according to Medical Marketing & Media, prompting disputes about the incentives pharma companies receive for developing rare-disease drugs. In the article, Nick Manetto, principal for FaegreBD Consulting, touted incentives such as those provided by the Orphan Drug Act (ODA) for encouraging more companies to develop rare-disease drugs.

“At ODA’s 2013 [30-year] anniversary, everyone trumpeted its incentives as critical to establishing a larger rare-disease market,” Manetto said.

The article also addressed the pediatric priority review voucher program, which was supposed to sunset in March but has been extended through September, despite a growing trend of companies selling vouchers to competitors for “eye-popping profits.”

“Parties shouldn’t be too critical of how companies are using the vouchers,” Manetto said.

Full Article

Meet the Authors

The Faegre Baker Daniels website uses cookies to make your browsing experience as useful as possible. In order to have the full site experience, keep cookies enabled on your web browser. By browsing our site with cookies enabled, you are agreeing to their use. Review Faegre Baker Daniels' cookies information for more details.